Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma

Pankaj, Sangeeta; Kumari, Jaya; Choudhary, Vijayanand; Kumari, Anita; Kumari, Simi; Kumari, Anjili; Nazneen, Syed; Madhawi, Richa; Kumar, Shishir

doi:10.1007/s13224-018-1186-5

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Her-2/neu gene was overexpressed in different types of cancer, including ovarian cancer. In a recent study conducted in 98 patients who were diagnosed with EOC, 22.4% were reported to have HER2 overexpression [23]. In another study, immunohistochemistry (IHC) and in situ hybridization (ISH) were performed in tissue microarrays of ovarian clear cell carcinoma (OCCC), endometrial clear cell carcinoma, and mixed endometrial carcinoma.…”

Section: Somatic Driver Mutationsmentioning

confidence: 99%

Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

et al. 2023

View full text Add to dashboard Cite

Ovarian cancers are tumors that originate from the different cells of the ovary and account for almost 4% of all the cancers in women globally. More than 30 types of tumors have been identified based on the cellular origins. Epithelial ovarian cancer (EOC) is the most common and lethal type of ovarian cancer which can be further divided into high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. Ovarian carcinogenesis has been long attributed to endometriosis which is a chronic inflammation of the reproductive tract leading to progressive accumulation of mutations. Due to the advent of multi-omics datasets, the consequences of somatic mutations and their role in altered tumor metabolism has been well elucidated. Several oncogenes and tumor suppressor genes have been implicated in the progression of ovarian cancer. In this review, we highlight the genetic alterations undergone by the key oncogenes and tumor suppressor genes responsible for the development of ovarian cancer. We also summarize the role of these oncogenes and tumor suppressor genes and their association with a deregulated network of fatty acid, glycolysis, tricarboxylic acid and amino acid metabolism in ovarian cancers. Identification of genomic and metabolic circuits will be useful in clinical stratification of patients with complex etiologies and in identifying drug targets for personalized therapies against cancer.

show abstract

Section: Somatic Driver Mutationsmentioning

confidence: 99%

Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

et al. 2023

View full text Add to dashboard Cite

show abstract

“…10 There are several approaches to drug discovery, such as combinatorial chemistry and computer-based molecular modeling design based on natural products, 2 in addition to drug discovery using natural products, which represents a challenging task for designing new leads. Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity, 11 which can regulate cell growth, survival, and differentiation via multiple signal transduction pathways and participate in cellular proliferation and differentiation. 12 Most studies on HER2 have been carried out in breast cancer and its overexpression occurs in approximately 15-30% of breast cancers.…”

Section: Introductionmentioning

confidence: 99%

“…[18][19][20] Therefore, HER2 has been recognized as a promising anticancer target with many reported inhibitors such as Trastuzumab, Lapatinib, Pertuzumab, Neratinib and Afatinib. 11 Therefore, the present study deals with the isolation and structural elucidation of eight compounds from Gladiolus segetum Ker-Gawl corms, which is a herbaceous plant cultivated in Egypt as an ornamental plant and known locally as Seif El-Ghorab. 10 Moreover, we evaluated the antiproliferative activity of the pure compounds on ve different cell lines.…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative activity of new pentacyclic triterpene and a saponin from Gladiolus segetum Ker-Gawl corms supported by molecular docking study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…HER2 overexpression (2+/3+) has been observed in 14% to 45.6% cases of OCCC in small patient cohorts (3,4). Controversial conclusions have been reached in several studies assessing the prognostic value of HER2 overexpression in OC (4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report

Wu¹,

You²,

Zhuang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Ovarian cancer (OC) is the seventh most common newly diagnosed cancer in women worldwide. Ovarian clear cell carcinoma (OCCC) is a specific type of epithelial ovarian cancer with a poor prognosis. It has been revealed that human epidermal growth factor receptor 2 (HER2)-positive (2+/3+) has been observed in 14% to 45.6% of patients with OCCC. Anti-HER2 therapy has been demonstrated to be an effective strategy for the treatment of HER2-positive breast cancer. However, the role of anti-HER2 therapy in OC remains largely unknown. This case report is the first report suggesting a 28-month PFS of pyrotinib in HER2-positive OCCC.Case Description: A 67-year-old female patient with HER2-positive OCCC was admitted to our hospital because of fever, who benefited greatly from treatment with pyrotinib, an irreversible HER2 antagonist conditionally approved for patients with advanced or metastatic HER2-positive breast cancer in China. The patient, who had previously been diagnosed with stage I A OCCC [according to the International Federation of Gynecology and Obstetrics (FIGO)] and undergone radical surgery with standard adjuvant chemotherapy on May 15, 2017, was diagnosed with HER2-positive OCCC at FIGO stage III C . She was treated with oral pyrotinib (400 mg/day in 21-day cycles) starting on November 27, 2018. Imaging assessments were conducted every 2 to 4 treatment cycles. Best response by response evaluation criteria in solid tumors (RECIST) 1.1 were partial response. However, on March 30, 2021, the patient was assessed using contrastenhance CT and found to have progressive disease with liver metastases. Subsequently, on April 26, 2021, the patient underwent liver microwave ablation and ultrasound-guided liver biopsy. The immunohistochemistry results of the liver biopsy showed the origin of the disease to be ovarian. Therefore, the disease was identified as HER2-positive OCCC at FIGO stage IV B .Conclusions: Progression-free survival (PFS) in second-line chemotherapy for patients with recurrent OC ranges from 3.8 to 11.3 months. In the case of this patient, treatment with pyrotinib yielded a PFS of 28 months, which was a promising result for the use of pyrotinib in treating HER2-positive OC.

show abstract

Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma

Cited by 5 publications

References 18 publications

Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

Antiproliferative activity of new pentacyclic triterpene and a saponin from Gladiolus segetum Ker-Gawl corms supported by molecular docking study

Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report

Contact Info

Product

Resources

About